It has been reported that S100A6 is over-expressed and associated with disease development and malignant progression in gastric cancer [33], pancreatic cancer [34], and colon cancer [35] but under-expressed in prostate cancer [36] and oral cancer [37]. Here, S100A6 is linked to lip and oral cavity carcinoma.